CRO Selection for Small Pharma and Biotech (2011)

Report Overview

Some Contract Research Organizations (CROs) possess measurable differentiating characteristics that should play an important role in the selection process for clinical studies. This is especially important for small pharma and biotech sponsors that have needs that may be meaningfully different than large pharma.

The challenge faced by the industry is that when making provider selections, development teams have only their own professional histories to reference. Unless a company, or the people it employs, has direct experience with a service provider, there is no independent assessment available to make a confident and informed purchase decision.

This report is designed to provide biopharmaceutical companies and service providers a view into how the consumers of these services grade their performance and how service providers are perceived by the broader market.

What you will learn:

• Performance of 19 CROs, as measured by respondents from small and mid-sized sponsors
• How small and mid-sized sponsors make their clinical outsourcing decisions, including which service attributes drive selection
• Attitudes, beliefs, and intentions for future outsourcing

How you can use this report:

• For buyers of clinical research service, this report offers insight into CRO service quality specifically for small and mid-sized sponsors. This empowers you to make smarter clinical outsourcing decisions by providing evaluation and selection tools.
• For clinical service providers, this critical report offers insight into your service quality for small and mid-sized sponsors, your competitors’ quality, buyers’ needs, CRO selection criteria, paths to differentiation, and clinical outsourcing trends and forecasts.

Report Contents:

1. Late Phase Trends and Market Sizing
2. Service Provider Dynamics
3. Decision Making for Late Phase Studies